Cel­gene and blue­bird make a 'break­through' on BC­MA-tar­get­ing CAR-T; An­oth­er can­cer drug biotech gar­ners $39M start­up round for I/O work

Cel­gene $CELG and its part­ners at blue­bird bio $BLUE can add boast­ing rights to the FDA’s break­through drug pro­gram for their close­ly watched work …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.